Hot topics close

Renal failure

ESC: Farxiga Demonstrated Reduction in Risk of Kidney Failure and Cardiovascular or Renal Death in Patients With Chronic Kidney Disease in Phase III D
4
  • ESC: Farxiga Demonstrated Reduction in Risk of Kidney Failure and Cardiovascular or Renal Death in Patients With Chronic Kidney Disease in Phase III D
  • Study: AstraZeneca's Farxiga sharply cuts risk of renal failure in patients with chronic kidney disease
  • FARXIGA Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease i
  • DAPA-CKD: Dapagliflozin Drops Risk of Renal Decline or Kidney Failure Death 39%, Even Without Diabetes
This week's most popular news